NASDAQ Composite opens in less than one hour and Moderna‘s pre-market value is already 6.93% down.
The last session, NASDAQ Composite finished with Moderna dropping 6.19% to $162.84. NASDAQ Composite dropped 0.37% to $13,582.42, after four sequential sessions in a row of losses, on what was a somewhat negative trend exchanging session.
Moderna’s last close was $173.59, 16.22% below its 52-week high of $189.26.
News about Moderna today
Moderna reaches supply agreement with Switzerland for 7 mln booster vaccine doses in 2022. According to today’s article on Business Insider, "The supply agreement follows two earlier agreements between Switzerland and Moderna to supply a total of 13.5 million doses of the COVID-19 Vaccine Moderna.", "It was based upon the recommendation of the Human Medicines Expert Committee, which authorizes the COVID-19 Vaccine Moderna for active immunization to prevent COVID-19 caused by SARS-CoV-2 virus in individuals 18 years of age and older."
Moderna’s sales growth is 24182.2% for the present quarter and 6321.4% for the next. The company’s growth estimates for the present quarter and the next is 782.9% and 1983.9%, respectively.
Moderna’s last day, last week, and last month’s current volatility was 7.16%, 3.47%, and 4.03%, respectively.
Moderna’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 9.82% (day), 5.94% (last week), and 5.96% (last month), respectively.
Previous days news about Moderna
Moderna to deliver Covid-19 vaccine to hard-hit developing world. According to The Wall Street Journal on Monday, 3 May, "Covax will retain an option to purchase another 466 million doses in 2022, according to a statement by Moderna and Gavi, one of the organizations behind the vaccine aid program."
Moderna to boost Covid-19 vaccine production at Massachusetts site by 50%. According to MarketWatch on Tuesday, 4 May, "Shares of Moderna Inc. were down 0.3% in premarket trading on Tuesday after the company said it will double the size of its manufacturing space at its facility in Norwood, Mass., essentially allowing for a 50% increase in the production of its COVID-19 vaccine there. ", "We believe that this investment and expansion at our technology center will allow us to continue to optimize our mRNA products as we explore new pharmaceutical delivery forms such as prefilled syringes and lyophilized products," Moderna CEO Stéphane Bancel said in a news release. "
Philippines clears Moderna Covid-19 vaccine for emergency use. According to Bloomberg Quint on Wednesday, 5 May, "The Philippines has approved Moderna Inc.’s coronavirus vaccine for emergency use, Food and Drug Administration head Eric Domingo said Wednesday."
More news about Moderna.